Bioshares Report, page-5

The current low SP annoys me but since the Amgen FDA advisory approval I have never been more confident about VLA than now. Management have always stated that Ph3 trials would be too expensive to go alone so a "buy out" or "big brother" partnership is just a matter of time with trial results going to plan that a deal would be done. One of the big sub holders IMO is selling in 100k and 250k lots in recent weeks but once they are done selling I am expecting this to run again. IMHO